Skip to main content
Journal cover image

UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC)

Publication ,  Journal Article
Plimack, ER; Hammers, HJ; Rini, BI; McDermott, DF; Redman, BG; Kuzel, TM; Harrison, MR; Vaishampayan, UN; Drabkin, HA; George, S; Logan, TF ...
Published in: Asia-Pacific Journal of Clinical Oncology
2015

Duke Scholars

Published In

Asia-Pacific Journal of Clinical Oncology

EISSN

1743-7563

ISSN

1743-7555

Publication Date

2015

Volume

11

Start / End Page

129 / 129

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Plimack, E. R., Hammers, H. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., … Motzer, R. J. (2015). UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC). Asia-Pacific Journal of Clinical Oncology, 11, 129–129.
Plimack, Elizabeth R., Hans J. Hammers, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy M. Kuzel, Michael R. Harrison, et al. “UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC).” Asia-Pacific Journal of Clinical Oncology 11 (2015): 129–129.
Plimack ER, Hammers HJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, et al. UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC). Asia-Pacific Journal of Clinical Oncology. 2015;11:129–129.
Plimack, Elizabeth R., et al. “UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC).” Asia-Pacific Journal of Clinical Oncology, vol. 11, 2015, pp. 129–129.
Plimack ER, Hammers HJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Xu L-A, Waxman IM, Motzer RJ. UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC). Asia-Pacific Journal of Clinical Oncology. 2015;11:129–129.
Journal cover image

Published In

Asia-Pacific Journal of Clinical Oncology

EISSN

1743-7563

ISSN

1743-7555

Publication Date

2015

Volume

11

Start / End Page

129 / 129

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis